Epilepsy is a chronic neurologic disorder characterized by recurrent episodes that may vastly affect health, daily functioning, and quality of life (Qol). although many antiepilepsy drugs (aEds) are available (see Abstract long-term adherence to antiepilepsy drug (aEd) regimens is frequently suboptimal. Poor adherence to therapy is associated with a number of negative consequences, including an increase in patient seizures and mortality. Nonadherence is related to a variety of factors, such as treatment-related adverse events, convenience of treatment, efficacy, and quality of life. There is therefore a need for treatment strategies in epilepsy that improve long-term adherence. one such strategy is the use of extended-release (ER) aEd formulations. advantages of ER aEds over other aEd formulations include the potential for once-daily dosing, a more stable mean drug concentration over time, improved tolerability profiles, maximal use of the therapeutic window, and the possibility to achieve better seizure control. improvements in overall treatment effectiveness may therefore increase patient adherence. This review presents evidence related to patient adherence and preference patterns for ER aEds and highlights the beneficial properties of ER aEds.
in the same study, aEs were noted as a factor in nonadherence in 16 % of patients (n=326). 19 among persistent aEs that have been reported by patients taking aEds that could potentially contribute to nonadherence were dizziness, somnolence, nausea, weight gain, irritability, diplopia, and cognitive impairment. 24 These aEs can be associated with peak aEd blood levels for some aEds. 25 another aspect related to nonadherence is the complexity or inconvenience of the drug regimen. in general, more frequent doses are associated with lower adherence 19, 21 as it increases the need to have sufficient medication onhand at work, school, or when performing daily activities. Furthermore, when taking aEds in public settings, some patients may be embarrassed and experience a feeling of stigmatization. 22, 23 Patients subsequently may avoid taking aEds in public, make excuses for using aEds, or stop taking medication to avoid this perceived social stigma. 22 one approach that has aided in improving adherence has been the reformulation of several immediate-release (iR) and delayed-release (dR) aEds that are dosed as twice daily or more frequently to extendedrelease (ER) preparations that are dosed as once daily. 13, 26 ER formulations (also denoted as XR) have the advantages of minimizing peak to trough variations seen with iR formulations, thereby reducing aEs associated with peak concentrations while allowing for more consistent plasma levels and reducing the number of daily doses. Furthermore, ER or XR formulations maximize the use of the therapeutic window by allowing necessary modest increases in the total daily dose for better efficacy while keeping maximum concentration (c max ) below the upper limit of the therapeutic range, thus avoiding peak-related aEs. These improvements in the pharmacokinetic properties of an individual particular aEd by reformulation to an ER (or XR) preparation can vary and are dependent on the characteristics of the original molecule, such as bioavailability, solubility, and permeability properties, and the particular ER technology used. in the preparation of ER formulations, crystalline matrix, modified-release eroding matrix, film-coated tablet, osmotic release delivery system, and enteric coating technologies have been used. ER aEds are dosed less frequently than iR formulations, either once or twice daily (see Table 1 ).
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This review will compare patient adherence patterns for ER aEds with those observed with their iR counterparts (or equivalents), as well as assess patient preferences for these formulations. Furthermore, factors associated with patient adherence, such as aEs, tolerability, effectiveness, efficacy, and
Qol will be discussed for the ER and other formulations of aEds.
Adherence Patterns and Patient Preference for Extended-release Antiepilepsy Drugs Compared with Immediate-release Antiepilepsy Drugs
Various studies have shown increased adherence when patients were switched from an iR aEd to an ER aEd formulation (see Table 2 ). Table 3 ). 21, 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Several investigators have proposed that improved tolerability is likely due to lower c max values and reduced peak-to-trough differences in plasma drug concentration over the post-dose period, resulting in less fluctuation of drug plasma levels. 13, 36, 40 in a double-blind, crossover study of iR versus ER carbamazepine conducted in 48 patients, significantly fewer patients experienced aEs with carbamazepine ER treatment compared with carbamazepine iR (6 due to aEs, 42 while in another study, 67 % of patients (n=694) discontinued treatment at the highest dose of oxcarbazepine iR due to aEs. 48 however, not all aEds clearly show an improvement in the tolerability profile with the ER formulation. Mixed results were seen in studies comparing divalproex ER versus divalproex dR (or equivalent). 33, 35 in a trial of 41 adult patients with epilepsy who switched from divalproex dR to divalproex ER, no change was found in the aE profile after 6 months, including gastrointestinal disorders and weight gain. 33 The effect of tremors on daily activities and the archimedes spiral score were also not significantly changed with divalproex ER (p=0.07 and p=0.79, respectively). one should not be too surprised to see no significant difference in the aE profile of two formulations of an aEd that are designed to reduce aEs associated with the iR formulation of that drug. Though the dR valproate formulation is not 'extended' release to the extent the ER formulation is, nonetheless, it is more 'extended' than the iR formulation, thus reducing the difference in the impact of the slower-absorption formulations (dR and ER) on aEs.
of interest, the ER formulation of lamotrigine does not appear to have an improved aE and tolerability profile compared with the iR formulation. in a pooled analysis of three clinical trials evaluating the long-term safety and tolerability of lamotrigine ER (n=662), 69 % of patients reported one or more aEs, which led to premature withdrawal in 7 % of patients, similar to previous reports with lamotrigine iR. 41 
Simplicity of Regimen and Convenience of Dosing
Studies that have evaluated the relationship between dosing frequency and adherence in patients with epilepsy suggest that increased dosing frequency usually contributes to decreased medication adherence. 17, 49 Based on the results of a questionnaire answered by 661 patients, there was a 27 % increase in the odds of missing a dose of aEd for each increase in the number of times per day the aEd was taken (p=0.09). 17 in a separate study, the effect of dosing frequency of aEds on adherence over a period of 3,428 days was evaluated using a medication event monitoring system. 49 adherence rates increased as the number of daily doses decreased from four times a day to once daily (39 %, 77 %, 81 %, and 87 %, respectively). however, in a recent study of 108 patients by Bautista et al., better adherence (higher mean medication possession ratio) was observed with thrice-and twice-daily dosing compared with once-daily dosing (1.02 and 0.93, respectively, versus 0.86; p<0.001). 50 
Increase in Effectiveness and Efficacy
While effectiveness may refer to the totality of effects produced when considering all factors of a product following its administration to patients, including efficacy, safety, tolerability, pharmacokinetics, and ease of use, efficacy refers to the ability of a product to produce a desired effect.
Therapeutic plasma drug concentrations of ER-aEds are more stable, which may lead to enhanced effectiveness through improved seizure control (see Table 3 ). 21, 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] in a double-blind crossover study by canger and colleagues, a significant decrease in seizure frequency from 9.3 to 6.3 (p=0.013) was seen with carbamazepine ER compared with carbamazepine iR in 48 patients after 1 month of optimal therapy. 40 Similarly, in a retrospective chart review of 61 patients with up to 1 year of follow-up after switching from carbamazepine iR to carbamazepine ER, 46 % of patients had a ≥50 % decrease in seizure frequency after switching and 27 % became seizurefree. 36 however, seizure frequency per month was comparable with that prior to the switch.
in a trial where 2,031 patients with epilepsy were switched from an iR to ER valproate formulation, improved adherence was observed that was accompanied by a 23 % increase in the proportion of patients who were seizure-free. importantly, this improvement was also accompanied by a statistically significant decrease (19 %; p<0.001) in the proportion of patients experiencing one or more seizures per month. 21 Furthermore, formulations, probably because of decreased aEs, increased tolerability, dosing convenience, increased efficacy, and improved Qol (see Figure 1 ).
This increased patient preference for and adherence to ER formulations, however, may differ depending on the given aEd, which may reflect differences in the aEds. For example, while aEs have generally been reported to be reduced with the ER formulation of carbamazepine, 30, 36, 40 no difference was seen between the ER and iR formulations of lamotrigine. 41 There are times when physicians may prefer the iR formulation. concerns exist that the 'forgiveness' period, or time period one can delay taking the prescribed dose, is shorter with ER versus iR formulations. 25 on the contrary, we believe that if patients forget to take their once-daily aEd in the morning, they have the whole day to take it before going to bed. likewise, if they forget to take their once-daily bedtime dose, they can take it upon awakening. We strongly recommend the use of a pill-box (with a schedule) for all patients to readily discover whether a particular dose was forgotten. also, some physicians believe that the ER formulation does not provide complete therapeutic coverage throughout the dosing interval. 25 it is in this situation that we recommend full use of the therapeutic range by making the necessary modest increases in the dose since the lesser peak-trough fluctuations in plasma concentrations make such adjustments with ER formulations more permissible. While it is easy to assume that XR formulations provide low c max (hence less side effects) and higher minimum concentration (c min ) (hence less breakthrough seizures theoretically) compared with iR formulations, some XR formulations showed a slightly lower c min (i.e., lamotrigine, levetiracetam, and divalproex) than iR counterparts. This could be partly due to the fact that not all XR formulations are bioequivalent to iR formulations milligram for milligram. one should refer to the manufacturer's instructions for dosage conversions when switching patients from iR to XR formulations of the same aEd. This may not be a factor when a healthcare provider starts a patient on an XR formulation de novo.
overall, it is extremely important that the patient is educated on his/her treatment options. When discussing aEd regimens with patients, it is important for physicians to give patients options and encourage them to communicate their concerns, problems, and preferences regarding their medication regimen.
in doing so, the individual treatment strategy may be tailored for each patient and may thereby result in better long-term adherence. Epilepsy therapy is not 'one size fits all,' and many patients require individualized medication regimens.
Extended-release aEds offer several potential advantages over iR counterparts. in addition to benefits in tolerability and the potential for improved efficacy, they may also include improved Qol, and, ultimately, better patient satisfaction. consequently, these improved attributes can lead to better patient adherence. n 
